MarketIQ Analyst Report for Waters Corporation

34 MAPLE ST, MILFORD, MA, US
WAT

Last Updated: 11 Nov 2024

Executive Summary

Waters Corporation (WAT) is a leading provider of analytical laboratory instruments and software. The company has a strong financial position with high profitability and a solid balance sheet. WAT's stock price has been trending upward in recent months, and analysts are generally positive on the company's prospects.

Company Overview

Waters Corporation is a publicly traded company headquartered in Milford, Massachusetts. The company was founded in 1958 and has since grown to become a global leader in the analytical laboratory instrument market. WAT's products are used in a variety of industries, including pharmaceutical, biotechnology, food and beverage, and environmental testing.

Fundamental Analysis

WAT's financial performance has been strong in recent years. The company has reported consistent revenue and earnings growth, and its profitability metrics are well above industry averages. WAT's balance sheet is also strong, with low debt levels and ample liquidity.

Technical Analysis

WAT's stock price has been trending upward in recent months. The stock broke out of a downtrend in early 2023 and has since made a series of higher highs and higher lows. The stock is currently trading above its 50-day and 200-day moving averages, which is a bullish sign.

Short Term Outlook

WAT's short-term outlook is positive. The company is expected to continue to benefit from strong demand for its products in the healthcare and life sciences industries. WAT's stock price is likely to continue to trend upward in the short term.

Long Term Outlook

WAT's long-term outlook is also positive. The company is well-positioned to benefit from the growing demand for analytical laboratory instruments and software. WAT's strong financial position and commitment to innovation should allow the company to continue to grow in the long term.

Analyst Recommendations

Analysts are generally positive on WAT's prospects. The consensus analyst rating on the stock is "buy," and the average analyst target price is $378.4.